Literature DB >> 17963025

Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat.

Sheila Annie Peters1, Leif Hultin.   

Abstract

Inhibition of gastric emptying rate can have adverse effects on the absorption of food and nutrients. The absorption phase of the plasma concentration-time profile of a compound administered orally to pre-clinical species reflects among others, the gastric and intestinal transit kinetics, and can thus assist in the early identification of delayed gastric emptying. The purpose of this article is to demonstrate the value of Physiologically Based Pharmacokinetic (PBPK) modelling in the early identification of drug induced impairment of gastric emptying from pharmacokinetic profiles. To our knowledge, this is first time that the value of a generic PBPK model for hypothesis testing has been demonstrated with examples. A PBPK model built in-house using MATLAB package and incorporating absorption, metabolism, distribution, biliary and renal elimination models has been employed for the simulation of concentration-time profiles. PBPK simulations of a few compounds that are currently in drug discovery projects show that the observed initial absorption phase of their concentration-time profiles in rat were consistent with reduced gastric emptying rates. The slow uptake of these compounds into the systemic circulation is reflected in their pharmacokinetic profiles but it is not obvious until PBPK simulations are done. Delayed gastric emptying rates of these compounds in rats were also independently observed in x-ray imaging. PBPK simulations can provide early alerts to drug discovery projects, besides aiding the understanding of complex mechanisms that determine the lineshapes of pharmacokinetic profiles. The application of PBPK simulations in the early detection of gastric emptying problems with existing data and without the need to resort to additional animal studies, is appealing both from an economic and ethical standpoint.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17963025     DOI: 10.1007/s10928-007-9073-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  34 in total

Review 1.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

Authors:  B Agoram; W S Woltosz; M B Bolger
Journal:  Adv Drug Deliv Rev       Date:  2001-10-01       Impact factor: 15.470

2.  A physiologic model for simulating gastrointestinal flow and drug absorption in rats.

Authors:  Stefan Willmann; Walter Schmitt; Jörg Keldenich; Jennifer B Dressman
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

Review 3.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Permanent cannulation of aorta and vena cava in rats and ground squirrels.

Authors:  V POPOVIC; P POPOVIC
Journal:  J Appl Physiol       Date:  1960-07       Impact factor: 3.531

5.  Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms.

Authors:  U Fagerholm; A Lindahl; H Lennernäs
Journal:  J Pharm Pharmacol       Date:  1997-07       Impact factor: 3.765

Review 6.  Intraluminal pH of the human gastrointestinal tract.

Authors:  J Fallingborg
Journal:  Dan Med Bull       Date:  1999-06

7.  Opioid-induced delay in gastric emptying: a peripheral mechanism in humans.

Authors:  D B Murphy; J A Sutton; L F Prescott; M B Murphy
Journal:  Anesthesiology       Date:  1997-10       Impact factor: 7.892

8.  Physiologic modeling of cyclosporin kinetics in rat and man.

Authors:  A Bernareggi; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

9.  Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.

Authors:  S Winiwarter; N M Bonham; F Ax; A Hallberg; H Lennernäs; A Karlén
Journal:  J Med Chem       Date:  1998-12-03       Impact factor: 7.446

10.  Effects of verapamil and diltiazem on gastric emptying in normal subjects.

Authors:  R T Yavorski; S E Hallgren; P W Blue
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

View more
  12 in total

1.  Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.

Authors:  Sheila Annie Peters
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 2.  To scale or not to scale: the principles of dose extrapolation.

Authors:  Vijay Sharma; John H McNeill
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

3.  Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis.

Authors:  Frederique Fenneteau; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-10-22       Impact factor: 2.745

4.  Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.

Authors:  Sheila Annie Peters
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.

Authors:  Daniel Moj; Hannah Britz; Jürgen Burhenne; Clinton F Stewart; Gerlinde Egerer; Walter E Haefeli; Thorsten Lehr
Journal:  Cancer Chemother Pharmacol       Date:  2017-10-07       Impact factor: 3.333

6.  Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.

Authors:  Guo-fu Li; Kun Wang; Rui Chen; Hao-ru Zhao; Jin Yang; Qing-shan Zheng
Journal:  Acta Pharmacol Sin       Date:  2012-10-22       Impact factor: 6.150

7.  Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors.

Authors:  O Demin; T Karelina; D Svetlichniy; E Metelkin; G Speshilov; O Demin; D Fairman; P H van der Graaf; B M Agoram
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-09-11

8.  Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them.

Authors:  Sheila Annie Peters; Hugues Dolgos
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

9.  Development of a Web-Based Toolbox to Support Quantitative In-Vitro-to-In-Vivo Extrapolations (QIVIVE) within Nonanimal Testing Strategies.

Authors:  Ans Punt; Nicole Pinckaers; Ad Peijnenburg; Jochem Louisse
Journal:  Chem Res Toxicol       Date:  2020-12-31       Impact factor: 3.739

10.  A systems pharmacology perspective on the clinical development of Fatty Acid amide hydrolase inhibitors for pain.

Authors:  N Benson; E Metelkin; O Demin; G L Li; D Nichols; P H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.